Scarica l'app Stockscreener
13.06
4.18%
-0.57
Precedente Chiudi:
$13.63
Aprire:
$13.52
Volume 24 ore:
528.09K
Relative Volume:
0.76
Capitalizzazione di mercato:
$892.07M
Reddito:
$568.09M
Utile/perdita netta:
$27.27M
Rapporto P/E:
39.87
EPS:
0.3276
Flusso di cassa netto:
$71.41M
1 W Prestazione:
-9.05%
1M Prestazione:
-6.45%
6M Prestazione:
+47.40%
1 anno Prestazione:
+86.57%
Intervallo 1D:
$13.04
$13.53
Intervallo di 1 settimana:
$13.04
$14.31
Portata 52W:
$6.255
$15.89
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
13.06 | 892.07M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
103.36 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | CJS Securities | Market Outperform |
| 2026-02-09 | Iniziato | Barrington Research | Outperform |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
Bank of New York Mellon Corp Takes Position in Bioventus Inc. $BVS - MarketBeat
Bioventus Stock Price Forecast. Should You Buy BVS? - StockInvest.us
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Bioventus (NASDAQ:BVS) Gains As Healthcare Demand Supports Growth - Kalkine Media
Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
BIOVENTUS INC. (BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (BVS) - TMX Newsfile
Bioventus Inc. (BVS) Holds Steady Near $13.84 as Investors Weigh Support and ResistanceExhaustion Gap - siam.in
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Bioventus Inc. Class A (BVS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Are Investors Undervaluing Bioventus (BVS) Right Now? - qz.com
Globeflex Capital L P Purchases New Shares in Bioventus Inc. $BVS - MarketBeat
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - easternprogress.com
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? - Eastern Progress
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19 - Moomoo
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Stock News Today - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Bioventus Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bioventus (BVS) Drops 8.9% to $13.9: Key Support Tested After Sharp SelloffUnusual Put Volume - dars.gov.et
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain - simplywall.st
Bioventus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Bioventus Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-08-05 - Seeking Alpha
Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... - Yahoo Finance
Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket - Investing.com Nigeria
Bioventus (NASDAQ:BVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bioventus Inc. Q2 2026 Earnings: Strong Revenue Growth, Net Income, and Financial Highlights - Minichart
Bioventus Shareholder Action Reminder - TMX Newsfile
Bioventus Inc. Reports Q2 2026 Results and Strategic Review in Latest 10-Q Filing - Kalkine Media
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):